Cryoprecipitate is given as an intravenous infusion through a standard blood administration set with a 170 to 200 micron filter. The product must be thawed at 30 to 37°C before use, and once thawed and pooled, it needs to be infused promptly, typically within 4 to 6 hours depending on how it was prepared. The process involves thawing, pooling (if not pre-pooled), verifying patient identity, and infusing at a rate the patient can tolerate.
What Cryoprecipitate Contains
Cryoprecipitate is a concentrated blood product made from plasma. Each unit is roughly 30 mL and contains fibrinogen, Factor VIII, Factor XIII, von Willebrand factor, and fibronectin. The UK specification requires a minimum of 140 mg of fibrinogen per unit. A standard adult dose is two pools of five units (10 units total), which raises fibrinogen levels by approximately 1 g/L in most patients.
The primary reason for giving cryoprecipitate is to replace fibrinogen, the protein responsible for forming the structural framework of blood clots. It’s used when fibrinogen levels drop dangerously low, a condition called hypofibrinogenemia. This happens most often during massive bleeding from trauma, obstetric hemorrhage, liver disease, or disseminated intravascular coagulation (DIC). European trauma guidelines recommend starting fibrinogen replacement when levels fall below 1.5 to 2.0 g/L (150 to 200 mg/dL).
Thawing and Preparation
Cryoprecipitate is stored frozen at minus 18°C or colder and has a shelf life of up to one year. To prepare it for infusion, thaw the units in a water bath or approved thawing device set to 30 to 37°C. Do not use a microwave, and do not thaw at temperatures above 37°C, as excessive heat destroys the clotting factors.
Once thawed, cryoprecipitate should be stored at room temperature, not refrigerated. Timing matters: if the units are pooled in an open system (meaning the seal is broken during pooling), the product expires within 4 hours. If pooled in a closed system or pre-pooled before storage, the window extends to 6 hours. Either way, the goal is to begin the infusion as soon as possible after thawing.
If you need to pool individual units, connect them using sterile technique and gently mix. Some blood banks issue pre-pooled cryoprecipitate, which saves time at the bedside.
ABO Compatibility
Cryoprecipitate contains very small amounts of plasma antibodies, so strict ABO matching is not required. Both the American Association of Blood Banks (AABB) and the Canadian Society for Transfusion Medicine state that adult recipients can receive any ABO group of cryoprecipitate. In practice, most centers worldwide transfuse cryoprecipitate regardless of blood group, and hemolytic transfusion reactions from cryoprecipitate have never been reported.
That said, ABO-compatible product is preferred when available, especially if large volumes are being transfused. No crossmatch is needed.
Setting Up the Infusion
Use a standard blood administration set equipped with a 170 to 200 micron filter. This is the same type of set used for red blood cells and other blood components. Do not use a set without a filter, and do not add medications to the cryoprecipitate bag.
Before starting, verify the patient’s identity and check the product label against your facility’s transfusion protocol. Record baseline vital signs including temperature, pulse, blood pressure, and respiratory rate. Prime the tubing with the cryoprecipitate itself or with compatible saline per your institution’s policy.
Infuse at a rate the patient can tolerate. Because the total volume is small (a pooled dose of 10 units is roughly 150 to 300 mL), the infusion is usually completed relatively quickly, often over 10 to 30 minutes. Start slowly for the first few minutes while monitoring for any signs of a transfusion reaction, then increase to the target rate if the patient is stable.
Dosing Guidelines
The standard adult dose is one unit per 5 to 10 kg of body weight, depending on how low the fibrinogen level is. For most adults, this works out to two pools of five units (10 units total). A helpful rule of thumb: two units per 10 kg of body weight will raise the fibrinogen concentration by about 1 g/L, except in patients with ongoing DIC or active massive hemorrhage where consumption outpaces replacement.
For a more precise calculation, you need the patient’s current fibrinogen level, the target level, and estimated plasma volume. In trauma settings, European guidelines recommend an initial fibrinogen replacement dose equivalent to 3 to 4 grams of fibrinogen, with further dosing guided by repeat lab testing. Since each cryoprecipitate unit contains at least 140 mg of fibrinogen, reaching 3 grams requires roughly 20 or more units.
Monitoring During and After Infusion
Monitor vital signs at the start of the infusion, 15 minutes in, and at completion. Watch for signs of transfusion reactions: fever, chills, hives, shortness of breath, chest tightness, or a drop in blood pressure. If any of these occur, stop the infusion immediately and follow your facility’s transfusion reaction protocol.
After the infusion is complete, check a fibrinogen level to confirm the product achieved the desired effect. The timing of this draw varies by clinical context, but a reasonable approach is to recheck within 30 to 60 minutes of completing the infusion. If the fibrinogen level hasn’t risen as expected, consider whether the patient has ongoing consumption from DIC or continued bleeding, which may require additional doses.
Risks of Cryoprecipitate Transfusion
Because cryoprecipitate is a plasma-derived product, it carries the same general risks as other plasma transfusions, though the smaller volume makes some complications less likely. The main concerns are transfusion-related acute lung injury (TRALI), transfusion-associated circulatory overload (TACO), and allergic reactions ranging from mild hives to anaphylaxis.
Infectious disease transmission is extremely rare with modern screening. In the United States, the estimated risk of acquiring HIV through transfusion is about 1 in 1.5 million donations, hepatitis C about 1 in 1.1 million, and hepatitis B about 1 in 280,000. Febrile nonhemolytic reactions (fever and chills without a dangerous cause) can also occur but are generally self-limiting.
TACO is worth particular attention when large volumes of cryoprecipitate are given rapidly, especially in elderly patients or those with heart failure. Slowing the infusion rate and monitoring fluid balance can reduce this risk.